Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gentium
Villa Guardia, Como, Italy
- Ownership
- Private
- Employees
- ~60
- Development stage
- Other
01
Overview
Defibrotide, Gentium's lead program, is approved in the EU for treatment of hepatic veno-occlusive disease post stem cell transplantation, with demonstrated efficacy in a rare, high-mortality condition. Other pipeline programs were in clinical or preclinical development for vascular and inflammatory conditions prior to Gentium's acquisition[1][4][6].
- Therapeutic areas
- HematologyOtherCardiovascularGastroenterologyOncology
- Modalities
- Small moleculeNucleic acid mixture
- Industry
- Biotech
02
Partnerships
Sigma-Tau PharmaceuticalsAxcan PharmaCrinos
Beyond the preview
Go deeper on Gentium.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gentium.